Medium-term plans, capital spending, new plants, products and drug approvals from Japanese companies.
The company pushed a ¥50mn budget for hiring, training and developing specialist engineers and support staff from June to December, saying the market for experienced technical talent remains tight. Management says the broader new-business plan is unchanged and the earnings impact should be minor.
G-JTEC will set up Japan Tissue Engineering Europe GmbH in Heidelberg with EUR25,000 of capital and 100% ownership to develop, make and sell research-use products locally. The company says exports of its LabSite cultured-tissue products from Japan have hit the predictable problem of living cells: short shelf life and transport risk, especially after recent international disruptions. Management says a shared-lab partnership in Heidelberg should keep initial investment low and speed production setup, with operations due to start within 2026 and consolidation from the year ending March 2027. Near-term earnings impact is expected to be minor; the operational payoff is reliability, not instant scale.